Lightcast Announces Limited Commercial Release of Envisia™ Single-Cell Functional Analysis Platform for Antibody Discovery
CAMBRIDGE, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Lightcast Discovery Ltd., a pioneering life science tools company, today announced the limited commercial release of its Envisia™ benchtop platform — a breakthrough droplet-based, single-cell functional analysis system designed to accelerate antibody discovery and development. The company will debut the instrument at booth #711 and present new data from its technology access program at the Essential Protein and Antibody Engineering Summit (PEGS), taking place May 12-16, 2025, in Boston.
'The Lightcast Envisia platform is truly one of a kind, enabling us to analyze single-cell functional activity in real time,' said Toon Swings, PhD, Technology Expert at VIB.
'The Lightcast Envisia platform is truly one of a kind, enabling us to analyze single-cell functional activity in real time,' said Toon Swings, PhD, Technology Expert at VIB. 'We are able to track cell behavior, administer treatments, and monitor responses over time, which helps identify and select cells of interest for downstream studies.'
While traditional single-cell analysis techniques often rely on genomic data to infer function, the Envisia platform uses droplet microfluidics to perform highly controlled, sequential single-cell functional assays that capture rich functional data sets to improve decision making. Built around Lightcast's proprietary light-controlled droplet manipulation technology, the platform enables parallel interrogation of tens of thousands of picoliter-scale droplets, offering unmatched precision and flexibility. By integrating functional screening early in the antibody discovery process, the Envisia platform allows researchers to select and advance the most promising candidates. It also opens new possibilities in cell-cell interaction studies and broader applications in immunology and oncology.
'The Lightcast team is excited to introduce Envisia to the scientific community at PEGS Boston and to highlight the cutting-edge work being done by our pharmaceutical and academic collaborators,' said Paul Loeffen, PhD, CEO of Lightcast. 'This limited product release marks a major milestone as we shift from technology development to customer-driven deployment. Researchers can secure their place now to gain a first-mover advantage and access to unprecedented functional insights that will power the next wave of innovative biologics and therapies.'
Featured PEGS Boston Presentations
Advances in Immunotherapy Luncheon
'Advancing Antibody Discovery with Single-Cell, Function-Focused Profiling'
Presenters:
Paul Loeffen, PhD, CEO of Lightcast
Kathrin Herbst, PhD, Director of Science at Lightcast
Poster Number: A60
Poster Presenter: Simon Margerison
Date/Time: May 12-13, 2025
As part of the limited release, Lightcast is working closely with leading pharmaceutical and academic institutions to validate performance, optimize protocols, and expand application areas, all in preparation for the launch of a diverse array of validated protocols later in 2025. The complete Envisia workflow will include advanced instrumentation, intelligent software, a purpose-built cartridge system, and assay kits optimized to a broad array of functional applications. The fully automated, end-to-end workflows will support a wide range of cell types, assay formats, and research applications. To learn more about the Envisia platform, visit www.lightcast.bio.
About Lightcast
Lightcast Discovery aims to unleash new capabilities within the single-cell analysis field by developing a more accessible, scalable, and flexible platform for scientists in basic, translational, and applied research. These capabilities will empower new biological discoveries and accelerate the development of novel drugs, therapies, and biologics. Founded in 2019 and based in Cambridge, UK, Lightcast has invented a technology that uses rays of light to control picoliter-scale droplets for functional analysis of individual cells. For more information, visit www.lightcast.bio.
Lightcast, the Lightcast logo, and Envisia are trademarks of Lightcast Discovery Ltd.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
PINEWOOD.AI ANNOUNCES AGREEMENT TO ACQUIRE LITHIA'S MAJORITY STAKE IN NORTH AMERICAN JOINT VENTURE
to Acquire Lithia's 51% Stake; New Contract Secures Deployment Across Lithia's Dealerships in US and Canada by 2028 LONDON and MEDFORD, Ore., June 6, 2025 /PRNewswire/ -- Pinewood Technologies Group plc ( a leading cloud-based software provider for the automotive retail industry, and Lithia UK Holdings Limited, a wholly-owned subsidiary of Lithia & Driveway (NYSE: LAD), today announced an agreement in which will acquire Lithia's 51% interest in their North American joint venture for $76.5 million. The acquisition will be satisfied through the issue of 14,560,691 new ordinary shares in and values the joint venture at $150 million. Full ownership of the joint venture gives complete control of its North American platform, removing potential barriers to its broader adoption and supporting its expansion across the region's $6.5 billion automotive retail software sector. The acquisition will also simplify structure and financial reporting, enabling full revenue consolidation and greater transparency. Alongside the proposed transaction, the two companies have signed a five-year contract committing to the rollout of the Pinewood Automotive Intelligence™ platform across all Lithia's current and future dealerships in the US and Canada projected by the end of 2028. The contract also includes an agreement on pricing for Lithia's use of expects to generate approximately $40 million in annual recurring revenue once the current rollout is complete. With additional North America-specific features planned for release by the end of 2028, projected annual revenue from Lithia is expected to reach approximately $60 million. The valuation attributed to the joint venture has been independently supported by Kroll LLC and is based on the deployment of DMS platform and layered applications across Lithia's North American footprint. "We are delighted to have reached an agreement with Lithia to acquire the majority stake of the North America joint venture. The US and Canada are central to our growth strategy, and through the joint venture, we have made significant progress towards commercializing the Pinewood Automotive Intelligence™ platform for the North American market. Assuming full control of the joint venture will strengthen our ability to fully capitalize on the opportunities available in a key strategic growth market," commented Bill Berman, Chief Executive Officer of Pinewood Technologies Group plc. "Today, we are also announcing that we have agreed the terms of a five-year contract with Lithia to implement the Pinewood Automotive Intelligence™ Platform across all its current and future sites by the end of 2028. This is a significant milestone on our journey to entering the North American market and we remain on track to pilot the platform in Lithia's US stores in the second half of 2025, with the full system rollout commencing in 2026. I would like to take this opportunity to thank Lithia for their partnership in the joint venture and we look forward to working with them as a key customer long into the future." "This agreement represents the next step in our strategic partnership with and supports our vision to modernize customer experiences across our ecosystem. As largest global customer, we are excited to partner in the rollout of their platform across our North American network and accelerate our transformation into a fully integrated, data-driven retailer. is now able to emerge as the leading automotive intelligence provider in the U.S. Each of our global stores are committed to the Pinewood Automotive Intelligence™ Platform, and we will continue partnering on best-in-class product development," said Bryan DeBoer, President and CEO of Lithia & Driveway. Following completion, Lithia will remain a committed minority shareholder and key long-term customer. About Pinewood Technologies Group PLC First established in 1981, Pinewood Technologies Group PLC (Pinewood) is a leading cloud based full-service technology provider to automotive retailers and OEMs. Pinewood's system is a market-leading automotive intelligence platform, which has been developed collaboratively with dealers and OEMs to provide secure cloud-based software across sales, aftersales, accounting and CRM. Headquartered in the UK, Pinewood has a team of over 200 people serving over 35,000 global users across 21 countries and long-standing partnerships with over 50 OEM brands. Previously part of Pendragon PLC, in 2024 Pinewood became an independent entity following the sale of Pendragon's UK Motor and Leasing divisions to Lithia Motors, Inc., one of the largest automotive retailers in North America. Pinewood simultaneously signed a strategic partnership with Lithia to roll out its software across Lithia's UK locations and form a joint venture to co-develop capabilities and accelerate Pinewood's entry into the North American market. LSE: PINE OTCQX: PINWF About Lithia & DrivewayLithia & Driveway (NYSE: LAD) is the largest global automotive retailer providing a wide array of products and services throughout the vehicle ownership lifecycle. Simple, convenient, and transparent experiences are offered through our comprehensive network of physical locations, e-commerce platforms, captive finance solutions, fleet management offerings, and other synergistic adjacencies. We deliver consistent, profitable growth in a massive and unconsolidated industry. Our highly diversified and competitively differentiated design provides us the flexibility and scale to pursue our vision to modernize personal transportation solutions wherever, whenever and however consumers desire. View original content to download multimedia: SOURCE Lithia Motors, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
/C O R R E C T I O N -- Meala/
In the news release, Meala Partners with dsm-firmenich to Commercialize Texturizing Protein for Meat Alternatives, issued June 3, 2025 by Meala over PR Newswire, we are advised by the company that edits have been made to the release. The complete, corrected release follows: PB Pea protein, a high-performance texturizer is ready for market release in Europe, bringing cleaner labels and better nutritional value to meat alternatives HAIFA, Israel, June 3, 2025 /PRNewswire/ -- Plant-based innovator Meala FoodTech Ltd. partners with dsm-firmenich to launch Vertis™ PB Pea — a groundbreaking texturizing pea protein. This single, multifunctional ingredient is designed to replace modified binders like hydrocolloids, helping to clean up labels in plant-based meat alternatives. The product is now available in Europe via dsm-firmenich as Vertis™ PB Pea. PB Pea, is a clean-label texturizer produced using biotechnology. Protected by two patents, it consolidates the functionality of multiple components into a single, versatile ingredient that delivers unmatched binding, gelation, and emulsifying properties. Furthermore, it increases the protein content of the final product. This holistic solution can replace an entire binding system often found in meat alternatives, while keeping the label short and recognizable. PB Pea was tested to great success in various meat alternative applications and suits any formulation, such as burgers, sausages and nuggets and more. Key benefits of PB Pea: Clean label and allergen-free: Clearly labeled as "pea protein." Thermostability: Maintains performance under heat and low temperature for versatile applications. Excellent texture and water retention: Provides juiciness and structure in meat alternatives. Enhanced nutritional value: Increases protein content. Short ingredient list: Enables producers to shorten and clean up the ingredient list. There is a clear shift in consumer behavior globally. Customers are increasingly drawn to products that deliver both an enjoyable taste experience and a clean, simple ingredient list that supports their well-being goals. To meet these rising expectations and drive meaningful growth, food manufacturers are seeking all-in-one ingredient solutions. "This is exactly where our product comes in," says Tali Feldman Sivan, CBO and co-founder of Meala FoodTech. "It addresses both functionality and clean-label demands, while replicating the sensory profile and experience of conventional meat products." With health and transparency rising in importance, European consumers are fueling a clean-label shift in the food industry. According to recent research1 from the EIT Food Consumer Observatory—a pan-European study on consumer perceptions of ultra-processed foods -- two-thirds of Europeans (67%) say they dislike unknown ingredients in their food, while just over half (56%) actively try to avoid processed foods. This growing awareness is reshaping preferences -- especially in the plant-based sector. In response, food manufacturers are under pressure to reformulate products and embrace cleaner, simpler labels to meet the rising demand for healthier, more natural options that don't compromise on taste or convenience With the launch of Vertis™ PB Pea, dsm-firmenich is expanding its Vertis™ plant protein portfolio -- introducing an innovative ingredient that consolidates the functionality of multiple components in plant-based meat alternatives. "We are grateful to our partners at dsm-firmenich, who offer decades of experience as industry leaders in bringing innovative products to market," exclaims Hadar Ekhoiz Razmovich, CEO and co-founder of Meala FoodTech. "Their application support, regulatory expertise, and ability to drive global commercial rollouts are unprecedented. We're impressed by their innovation-driven approach and deep understanding of the food industry. dsm-firmenich believed in us from the very beginning -- not only as investors, but as true partners -- offering guidance, trust, and strategic support that helped lay the foundation for this powerful collaboration." Meala's partnership with dsm-firmenich -- a global leader in food ingredients -- combines both distribution and venture investment. The agreement paves the way for Meala's innovative pea-based texturizer to enter new global markets and fuel the next wave of plant-based product innovation. With production already underway in Europe, Meala's functional pea protein is scaling to meet growing international demand. "We're looking forward to working with dsm-firmenich to lead the new era of plant-based alternatives that successfully merge high performance and robust nutrition, to create a new generation of delicious, better-for-you and better for the planet meat alternatives," adds Razmovich. "Meala delivers a powerful, high-protein texturizing solution, providing manufacturers with a scalable alternative to less-desirable additives. About Meala FoodTech Meala FoodTech was founded in 2021 by product-innovation specialists Hadar Ekhoiz Razmovich, Tali Feldman Sivan, PhD; and Liran Gruda, CTO. United by a shared vision, the trio set out to revolutionize food production with clean-label, functional ingredients that create better-for-you foods. Meala is backed by leading investors, including The Kitchen Hub, dsm-firmenich Ventures, Lasenor Emul SPA, EIT food, and Milk & Honey Ventures. For more information, contact: Company Contact: Press Contact: Meala FoodTech NutriPR Rom Elias Liat Simha Business Development & Marketing Project Manager Tel: +972-9-9742893 E-mail: Info@ E-mail: liat@ Web: Web: 1 Photo: View original content to download multimedia: SOURCE Meala
Yahoo
2 hours ago
- Yahoo
Biodefense Market worth $1.81 billion by 2030 - Exclusive Report by MarketsandMarkets™
DELRAY BEACH, Fla., June 6, 2025 /PRNewswire/ -- The biodefense market is projected to grow from USD 0.89 billion in 2025 to USD 1.81 billion by 2030 at a CAGR of 15.1% during the forecast period according to a new report by MarketsandMarkets™. The biodefense market is driven by increasing bioterrorism, growing geopolitical tensions, biological warfare risks, and advancements in technology. Biodefense encompasses a range of tools and systems designed to detect, prevent, and respond to biological threats, including infectious diseases, bioterrorism, and accidental pathogen releases. These include biosensors, rapid detection platforms, decontamination systems, mobile containment units, and AI-driven surveillance tools. The market for biodefense technology is experiencing strong growth due to increasing global concerns over pandemics, biological warfare, and emerging infectious diseases. Download PDF Brochure: Browse in-depth TOC on "Biodefense Market" 196 – Tables56 – Figures217 – Pages Biodefense Market Report Scope: Report Coverage Details Market Revenue in 2025 $ 0.89 billion Estimated Value by 2030 $ 1.81 billion Growth Rate Poised to grow at a CAGR of 15.1% Market Size Available for 2020–2030 Forecast Period 2025–2030 Forecast Units Value (USD Million/Billion) Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends Segments Covered By Technology, Product, Application and Region Geographies Covered North America, Europe, Asia Pacific, and Rest of World Key Market Challenge Infrastructure constraints in low-resource areas Key Market Opportunities Emergence of AI-powered biosurveillance and predictive analytics Key Market Drivers Rising threat of Bioterrorism Based on application, the hospitals & medical institutes segment is expected to account for the largest share of the biodefense market during the forecast period. Based on application, the hospitals & medical institutes segment is expected to account for the largest share of the biodefense market during the forecast period. Hospitals are the initial point of contact for the identification of unusual infections or exposure to biological agents, and hence, they must have sophisticated containment systems, sterilization apparatus, and pathogen detection instruments in real time. With increasing bioterrorism, governments and health agencies are investing heavily in the upgrade of hospital biosafety facilities, such as Class III biological safety cabinets, mobile isolation units, and UV sterilization technology, all of which are becoming essential for modern biodefense infrastructure. These facilities need safe conditions to work with high-risk pathogens, which fuels the demand for low-temperature sterilizers, decontamination chambers, and air purification. The growing incorporation of digital surveillance platforms and smart biodefense technologies in healthcare facilities further solidifies their role in early detection and quick response, making hospitals & medical institutes the largest application segment of the biodefense market. Based on technology, the AI technologies segment is projected to register the highest CAGR during the forecast period. Based on technology, the AI technologies segment is projected to register the highest CAGR during the forecast period due to its significant contributions toward monitoring real-time pathogens, forecasting, and fast decision-making. AI facilitates the convergence and synthesis of large-scale environmental data and enables early threat detection and quick response coordination. Governments and health organizations globally are increasingly using AI platforms to track bio-threats across borders and to automatically report disease transmission for strategic purposes. Additionally, AI technologies are being integrated into biosensor networks, autonomous disinfecting robots, and predictive modeling applications utilized in hospitals, airports, and military bases. The increasing focus on digitally empowered biodefense infrastructure, coupled with significant investments by public and private sectors, is expected to fuel the growth of the AI segment in the global market. Inquiry Before Buying: Asia Pacific is projected to register the highest CAGR during the forecast period. Asia Pacific is projected to register the highest CAGR in the biodefense industry through the forecast period due to increasing investments in public health infrastructure, infectious disease surveillance, and military biosafety capacities. China, India, Japan, and Australia are comprehensively developing their biodefense capabilities. These countries are investing in mobile biosafety laboratories, near-real-time pathogen detection systems, and next-generation decontamination technologies to anticipate future biological threats. Also, the region is experiencing growth in biotechnology R&D, cross-border health security efforts, and government-backed biodefense programs. The growth of local biotech and med-tech firms is also propelling innovation in AI-powered disease monitoring, biosensors, and portable sterilizers for civilian and military applications. The growing population, susceptibility to zoonotic disease, and proactive policy changes are driving significant growth in the regional biodefense market. STERIS (US), ASP International GmbH (a subsidiary of Fortive) (US), Ushio Inc. (Japan), Sotera Health Company (US), and Bioquell, An Ecolab Solution (UK) are the major key players in the biodefense companies. These companies have strong distribution networks across regions like North America, Europe, Asia Pacific, and the Rest of the World. Get 10% Free Customization on this Report: Browse Adjacent Market: Aerospace and Defence Market Research Reports & Consulting Related Reports: Border Security Market by Domain (Land, Maritime, Airborne), Vertical (Military, Homeland Security), System (Surveillance Systems, Detection Systems, Communication Systems, Command and Control Systems), Installation & Region – Global Forecast to 2029 CBRN Defense Market by Type (Chemical, Biological, Radiological, Nuclear, Explosives), Equipment (Protective Wearables, Respiratory Systems, Detection & Monitoring Systems, Decontamination Systems, Simulators, Others), End Use and Region - Global Forecast to 2028 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Web Site: Insight: Source: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio
